Implementation and Outcome of Minimally Invasive Pancreatoduodenectomy in Europe:

Implementation and Outcome of Minimally Invasive Pancreatoduodenectomy in Europe: A Critical Appraisal of the First 3 Years of the E-MIPS Registry

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06135233

Acronym

E-MIPS

Enrollment

1336

Registered

2023-11-18

Start date

2019-01-01

Completion date

2022-01-01

Last updated

2023-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreas Disease

Keywords

registry, minimally invasive surgery, robot-assisted, laparoscopy, pancreatoduodenectomy, pancreatic surgery

Brief summary

A planned analysis of outcomes among consecutive patients after MIPD from centers participating in the E-MIPS registry (2019-2021). Main outcomes of interest were major morbidity (Clavien-Dindo grade ≥3) and 30-day/in-hospital mortality.

Detailed description

The European registry for Minimally Invasive Pancreatic Surgery (E-MIPS) is an E-AHPBA endorsed registry with the aim to monitor and safeguard the introduction of MIPD in Europe. International multicenter audit-based studies focusing on outcomes of minimally invasive pancreatoduodenectomy (MIPD) are lacking. A planned analysis of outcomes among consecutive patients after MIPD from centers participating in the E-MIPS registry (2019-2021). Main outcomes of interest were major morbidity (Clavien-Dindo grade ≥3) and 30-day/in-hospital mortality.

Interventions

OTHERNo intervention

all patients undergoing minimally invasive pancreatic surgery, no intervention, no randomization

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

\- Data from all patients who underwent R-MIPD and L-MIPD between January 1st 2019 and December 31st 2021 were included

Exclusion criteria

* Other pancreatic procedures * Hybrid approaches (reconstruction phase open) * Procedures with insufficient baseline data / missing primary outcome data.

Design outcomes

Primary

Measure	Time frame
Major morbidity	30 days
30-day/in-hospital mortality.	30 days

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026